Professional Role and Expertise
Kevin Bitterman, PhD, is a Partner at Atlas Venture, a venture capital firm focused on translating pioneering scientific research into innovative medicines. His primary role at Atlas Venture involves creating and investing in companies that bridge groundbreaking science with therapeutic development. He is prominently positioned among the firm's leadership team, directly influencing investment decisions in life sciences and biotechnology sectors.
Kevin’s expertise centers on drug development and the advancement of novel biomedical technologies, leveraging his scientific background to identify and support promising ventures in these domains. He actively contributes to industry thought leadership, including judging start-up competitions such as BioPharm America and speaking engagements at forums like Fierce Biotech's Drug Development Forum.
Scientific and Technical Contributions
Kevin Bitterman holds a significant scientific presence, particularly in the field of cellular aging, epigenetics, and metabolic regulation, with a notable focus on sirtuin biology and NAD+ metabolism. His scientific accomplishments include co-authoring influential studies and holding multiple patents in related areas:
- Key publications document his work on inhibition of silencing and accelerated aging by nicotinamide, linking the regulation of SIRT1 (sirtuin 1) to mechanisms of cellular longevity and aging processes.
- His patents cover methods and compositions for extending lifespan in eukaryotic and prokaryotic cells, focusing on compounds such as nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide—all NAD+ precursors with implications for anti-aging and metabolic interventions.
- The patents reflect his leadership in developing novel biomedical approaches targeting cellular protection, lifespan modulation, and neuropathic disease treatments.
Collaborations with renowned scientists like David A. Sinclair, PhD underscore Kevin’s integration within leading-edge biomedical research networks. His published work is frequently cited in areas covering sirtuin regulators, resveratrol effects, and gene editing technologies.
Industry and Leadership Activities
Kevin Bitterman actively engages at the intersection of scientific innovation and venture capital, serving as:
- A judge for biotech start-up competitions, highlighting his role in scouting and evaluating early-stage biotechnology ventures.
- A speaker and thought leader at industry events which focus on drug development and biotech innovation.
- A contributor to advancing CRISPR and gene editing technologies in translation from lab research to industry application, including his prior involvement as an interim CEO in related startups.
Recent media citation (Dec 2024) references Bitterman discussing innovative delivery solutions for autonomous EV robots, indicating his broader interest in emerging technologies beyond biotechnology, possibly in strategic investment or advisory capacities.
Company Context: Atlas Venture
Atlas Venture is positioned as a leading venture capital firm specializing in early-stage life sciences investments. The firm emphasizes supporting the translation of novel scientific discoveries into clinical medicine, which aligns with Kevin Bitterman’s expertise and responsibilities. The firm’s high-profile leadership team invests in groundbreaking modalities and therapies, with Kevin as an integral player in shaping this direction.
Relevant Publications and Patents (Selected)
- Nature and Science Articles: Publications on cellular aging mechanisms, sirtuin function, and NAD+ metabolism.
- Patents: US Patent Nos. 7,977,049; 9,062,130; and multiple international filings related to the use of nicotinamide derivatives for life span extension and cell protection.
- ResearchGate Profiles and Articles: Extensive involvement in aging research, including calorie restriction and metabolic pathways, often cited alongside David Sinclair’s work.
Summary of Professional Insights for Engagement
Kevin Bitterman is a scientifically grounded, investment-focused partner with a deep domain expertise in aging biology, epigenetics, and metabolic therapeutics. His unique combination of venture leadership and technical acumen provides critical insight into early-stage biotech innovation, particularly in modalities that target cellular longevity and innovative drug development platforms. His role at Atlas Venture makes him a key decision-maker and influencer in the strategic direction of biomedical investments.
His extensive patent portfolio and publication history indicate a strong foundation in both research and intellectual property development, positioning him well to evaluate and drive high-potential projects in therapeutic innovation. His public presence in panels and competitions reflects active engagement in scouting next-generation biotech opportunities.
LinkedIn Profile: [Kevin Bitterman, PhD](https://www.linkedin.com/in/kevin-bitterman-74189840/)
Atlas Venture Team Page: [Kevin Bitterman, PhD](https://atlasventure.com/team/kevin-bitterman-phd/)
